Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up

In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.

court house

Acorda Therapeutics Inc.'s celebration in defeating Kyle Bass' challenge of its Ampyra (dalfampridine) patents in inter partes review (IPR) proceedings was short-lived as a district court found them to be invalid, clearing the way for possible generic entry in July 2018. The different outcomes show the perils of both pathways for patent owners.

In a March 31 opinion, US District Court for the District of Delaware Judge Leonard Stark ruled that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet